II. Indications

III. Contraindications

  1. Cardiovascular Disease

IV. Dosing: Adult

  1. Hyperprolactinemia
    1. Start: 0.25 orally twice weekly
    2. Titrate: Increase by 0.25 mg every month up to 1 mg twice weekly
    3. Follow Serum Prolactin levels
      1. May stop Cabergoline after Serum Prolactin normal for 6 months
  2. Acromegaly (not FDA approved)
    1. Start 0.5 mg orally twice weekly
    2. Base titration on plasma IGF1 Levels
      1. May increase up to 3.5 mg/dose each week as needed

V. Pharmacokinetics

  1. Hepatic metabolism

VI. Adverse Effects

  1. Fewer adverse effects than Bromocriptine (but less observational data in pregnancy)
  2. Safety
    1. Pregnancy Category B
    2. Avoid in Lactation
  3. Nausea or Vomiting
  4. Postural Hypotension
  5. Dizziness
  6. Headache
  7. Sedation
  8. Hypersexuality and Compulsive Gambling (risk with most Dopamine Agonists)
  9. Valvular disorders
    1. Reported with high dose Cabergoline (>4 mg daily)
    2. Follow Echocardiogram every 6 to 12 months
  10. Fibrosis
    1. Pleural fibrosis
    2. Retroperitoneal fibrosis
    3. Cardiac fibrosis

VIII. References

  1. Hamilton (2020) Tarascon Pocket Pharmacopoeia
  2. Huang (2012) Am Fam Physician 85(11): 1073-80 [PubMed]

Images: Related links to external sites (from Bing)

Related Studies

Cost: Medications

cabergoline (on 12/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing)
CABERGOLINE 0.5 MG TABLET Generic $2.01 each

Ontology: cabergoline (C0107994)

Definition (NCI) A synthetic ergoline derivative and a long-acting dopamine receptor agonist with high affinity for the dopamine D2 receptor. Cabergoline exerts an inhibitory effect on prolactin secretion by acting on dopamine receptors present in pituitary lactotrophs. This drug also binds to dopamine D2 receptors in the corpus striatum, thereby mimicking the actions of dopamine on motor control. Cabergoline also possesses antioxidant and neuroprotective properties due to its free radical scavenging activity. Cabergoline is used in the treatment of Parkinson's disease and in the treatment of hyperprolactinemia.
Concepts Pharmacologic Substance (T121) , Organic Chemical (T109)
MSH C047047
SnomedCT 323191001, 109139002, 386979007
English cabergoline, 1-((6-Allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea, Cabergoline [parkinsons], cabergoline (medication), dopamine agonists cabergoline, 1-((6-allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea, CABERGOLINE, cabergoline [Chemical/Ingredient], cabergoline parkinsons, Cabergoline [parkinsons] (product), Cabergoline, Cabergoline (product), Cabergoline (substance), Cabergoline [parkinsons] (substance)
Spanish cabergolina [antiparkinsonianos] (producto), cabergolina [antiparkinsonianos], cabergolina (producto), cabergolina (sustancia), cabergolina

Ontology: Dostinex (C0526034)

Concepts Pharmacologic Substance (T121) , Organic Chemical (T109)
MSH C047047
English Dostinex, Cabaseril, Pfizer brand of cabergoline, cabaser, dostinex, Cabaser